EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and safety of second-line taxane monotherapy for advanced or metastatic gastric cancer: experience from Ho Chi Minh City Oncology Hospital

Duc Thi Hong Phan, Anh Tuan Le, Khoa Le Anh Ho, Quy Hoang Nguyen

MedPharmRes · 30.09.2026 · 10 (3) · 283-292

DOI: 10.32895/mpr.26.02374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedPharmRes, online erschienen am 30.09.2026. Verfasst von Duc Thi Hong Phan und 3 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ho Chi Minh City Oncology Hospital.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in targeted therapies, gastric cancer remains a disease with a poor prognosis with high mortality rate. Single agent taxane regimens, including paclitaxel or docetaxel, have demonstrated clinical efficacy, and are recommended by major international oncology guidelines. Therefore, this study aimed to evaluate the preliminary effectiveness and safety of taxane monotherapy in this patient population. This was a case-series study including 33 patients with advanced or metastatic gastric cancer who received second-line treatment with paclitaxel or docetaxel at the Department of Breast, Gastrointestinal, Hepatobiliary, and Urologic Oncology, and Palliative Care Department, Ho Chi Minh City Oncology Hospital, from January 1, 2023 to December 31, 2024. The mean age was 61 years. Male patients accounted for 67% of the study population. ECOG performance status 0-1 observed in 87.9% of cases. 78.8% of patients had a single metastatic site, with regional lymph nodes being the most common site of metastasis (51.5%). The complete response rate was 3.0%, and the disease control rate was 57.6%. The median progression-free survival was 4.8 months (95% CI: 3.1–7.3 months), while the median overall survival was 6.6 months (95% CI: 4.5–8.0 months). The most common toxicities were anemia, neutropenia, peripheral neuropathy, and elevated liver enzymes. Single-agent taxane regimens represent a safe and reasonable treatment option for patients with advanced, metastatic gastric cancer after failure of first-line therapy, particularly in older adult patients, and those with multiple comorbidities.

Förderung

  • Ho Chi Minh City Oncology Hospital

Zitieren

APA

Phan, D. T. H., Le, A. T., Ho, K. L. A., & Nguyen, Q. H. (2026). Effectiveness and safety of second-line taxane monotherapy for advanced or metastatic gastric cancer: experience from Ho Chi Minh City Oncology Hospital. MedPharmRes, 10(3), 283-292. https://doi.org/10.32895/mpr.26.02374

Vancouver

Phan DTH, Le AT, Ho KLA, Nguyen QH. Effectiveness and safety of second-line taxane monotherapy for advanced or metastatic gastric cancer: experience from Ho Chi Minh City Oncology Hospital. MedPharmRes. 2026;10(3):283-292. doi:10.32895/mpr.26.02374

BibTeX
@article{Phan2026,
  author = {Phan, Duc Thi Hong and Le, Anh Tuan and Ho, Khoa Le Anh and Nguyen, Quy Hoang},
  title = {Effectiveness and safety of second-line taxane monotherapy for advanced or metastatic gastric cancer: experience from Ho Chi Minh City Oncology Hospital},
  journal = {MedPharmRes},
  year = {2026},
  volume = {10},
  number = {3},
  pages = {283--292},
  doi = {10.32895/mpr.26.02374}
}
Kostenlos starten →